Loading...
XJPX
3088
Market cap6.13bUSD
Oct 09, Last price  
2,476.50JPY
1D
0.65%
1Q
2.19%
Jan 2017
-14.01%
IPO
123.11%
Name

MatsukiyoCocokara & Co

Chart & performance

D1W1MN
XJPX:3088 chart
P/E
17.46
P/S
0.87
EPS
141.81
Div yield, %
1.91%
Shrs. gr., 5y
5.29%
Rev. gr., 5y
15.45%
Revenues
1.12t
+5.26%
345,460,000,000390,934,000,000392,268,000,000393,007,000,000428,184,000,000434,597,000,000456,311,000,000495,385,000,000485,512,000,000536,052,000,000535,133,000,000558,879,000,000575,991,000,000590,593,000,000544,737,000,000729,969,000,000951,247,000,0001,022,531,000,0001,061,626,000,0001,117,440,000,000
Net income
55.78b
+2.01%
4,133,000,0006,801,000,0007,728,000,0007,281,000,0007,291,000,0009,955,000,00011,270,000,00013,355,000,00011,619,000,00017,853,000,00020,119,000,00022,755,000,00025,035,000,00026,176,000,00021,602,000,00034,377,000,00040,546,000,00052,348,000,00054,676,000,00055,776,000,000
CFO
73.20b
-10.15%
16,964,000,00018,313,000,0009,423,000,0007,555,000,00011,266,000,00016,246,000,00019,174,000,00026,214,000,0009,009,000,00031,074,000,00023,722,000,00027,938,000,00021,897,000,00024,764,000,00025,875,000,00039,812,000,00064,061,000,00063,506,000,00081,472,000,00073,201,000,000
Dividend
Mar 30, 202728 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

MatsukiyoCocokara & Co., a Japanese enterprise, manages an extensive chain of pharmacies and drugstores throughout the nation. By June 30, 2020, its operations included 1,726 establishments distributed across all 47 prefectures of Japan. The company was founded in 1932 and maintains its headquarters in Matsudo, Japan.

Key people

Kiyoo Matsumoto
President, President of Subsidiaries, Representative Director · since 2017
Atsushi Tsukamoto
Vice President, President of Subsidiaries, Representative Director · since 2021
Akio Ishibashi
Managing Director · since 2022
Mitsuhiro Abe
Executive Officer, Manager of Human Resource Strategy Office in Group Administration Supervision · since 2023
Daiki Matsuura
Executive Officer, Director of Wellness Strategy in Group Sales Planning Supervision · since 2023
Shunichi Mori
Executive Officer, Manager of Policy Collaboration in Group Administration Supervision · since 2024
Masafumi Morita
Executive Officer, Manager of Legal Affairs Planning Office in Group Administration Supervision · since 2023
Yasuhiko Nakamura
Executive Officer, Manager of Business Planning Office in Group Business Planning Supervision, Manager of General Affairs Planning in Group Administration Supervision · since 2023
Hiroshi Nishida
Executive Officer, Senior Manager of Group Management Finance Strategy Office · since 2022
Yasuyuki Oike
Executive Officer, Director of IT & Logistics in Sales Support Strategy Office, Manager of Wellness Strategy in Group Sales Planning Supervision · since 2024
Seiichi Temma
Executive Officer, Manager of Business Planning Office in Group Business Planning Supervision · since 2023
Ryoichi Wachi
Executive Officer, Manager of Internal Control Supervision Office · since 2022
Takashi Matsuda
Director · since 2022
Namio Matsumoto
Chairman of the Board, Chairman of Subsidiary · since 2023
Takashi Matsumoto
Vice President, Representative Director · since 2026
Shingo Obe
Senior Managing Director · since 2026
Director · since 2021
Junko Kawai
Independent Director · since 2021
Keiji Kimura
Independent Director · since 2018
Independent Director · since 2020
IPO date
Oct 01, 2007
Employees
13,657
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT